stockrow
Friday 6 November 2026
Export VIR’s income statement to Excel — free account
Vir Biotechnology, Inc.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +200.5%
Quarter to September 2026, against a year earlier
12.19
1.17
+10.62%
Follow VIR
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
12.18 | 20.16 | 5.64 | 6.25 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(32.28) | (9.97) | 13.86 | (17.84) | |
P/B ratio |
1.09 | 1.62 | 1.74 | 2.11 | |
Price to Tangible BV |
1.13 | 1.68 | 1.78 | 2.17 | |
EV/Sales |
5.34 | 12.86 | 3.87 | 4.73 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.94) | (1.89) | (5.80) | (10.16) | |
EV/FCF |
(0.92) | (1.87) | (5.77) | (10.09) | |
Quick Ratio |
5.05 | 6.50 | 5.63 | 5.71 | |
Current Ratio |
5.54 | 7.11 | 6.04 | 6.30 | |
Net Debt/EBITDA |
10.79 | 3.70 | (6.98) | 4.48 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.06 | 0.06 | 0.25 | 0.28 | |
Operating CF/Net income |
0.60 | 1.05 | 1.54 | 1.10 | |
Capex/Depreciation |
(0.10) | (0.12) | (0.01) | (0.02) | |
Research and Development Expense of Revenue |
137.89% | (375,593.10%) | 56.62% | (42,574.47%) | |
Selling, General and Administrative Expense of Revenue |
36.86% | (80,479.31%) | 12.64% | (12,994.68%) | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
17.49% | (41,679.31%) | 5.19% | (5,561.17%) | |
Graham Net Nets |
0.33 | 0.23 | 0.20 | 0.15 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(52.40%) | (34.93%) | (18.16%) | (11.17%) | |
Free Cash Flow Yield |
(47.45%) | (34.06%) | (11.92%) | (7.50%) | |
Revenue per Share |
0.46 | 0.00 | 1.42 | 0.00 | |
Operating CF per Share |
(0.19) | (0.90) | 0.74 | (0.63) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.19) | (0.90) | 0.74 | (0.63) | |
Cash per Share |
3.39 | 3.25 | 3.19 | 2.72 | |
Shareholders Equity per Share |
5.52 | 5.52 | 5.86 | 5.29 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.52 | 5.52 | 5.86 | 5.29 | |
Free Cash Flow |
(26.33) | (132.78) | 123.29 | (106.11) | |
Working Capital |
421.27 | 449.43 | 478.78 | 427.61 | |
Capital Expenditures |
(0.46) | (0.39) | (0.03) | (0.03) | |
Net Current Asset Value |
276.53 | 310.17 | 341.43 | 292.45 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | (13.45) | 0.00 | (0.18) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
7.44 | 4.59 | 14.99 | 9.09 | |
Average Assets |
1,200.82 | 1,166.66 | 1,203.67 | 1,065.65 | |
Average Common Equity |
957.83 | 928.29 | 964.98 | 846.07 |
Columns are period end dates · fundamentals updated 6 Nov 2026